Aspirin and breast cancer recurrence

Article

Can it really be that aspirin can reduce the risk of breast cancer spreading to another organ and cut the death rate by half? According to a study out today in the Journal of Clinical Oncology online, it's true. The results come from the Nurse's Health Study. This is the ongoing observational study of more than 200,000 nurses who signed on to be followed back in the mid '70s. The study has revealed lots of great info about a number of diseases, among them breast cancer. Some 4,000 of the nurses in the study were diagnosed with stage 1, 2, or 3 breast cancer between 1976 and 2002. The study looked at their use of aspirin after treatment ended and compared it to frequency of metastatic disease and death from breast cancer. What they found is amazing. Women who took aspirin six or seven days a week had a 43 percent reduced risk of metastasis and a 64 percent lower risk of breast cancer death. Note here: If you are in treatment for breast cancer, the study emphasizes that you not take aspirin because of potential interactions that can increase side effects. While researchers don't know exactly why aspirin has the effect it does, they suspect it reduces inflammation, which is linked to cancer development. The researchers also did not collect data on the dose, but surmised that women who take aspirin regularly are doing so for heart disease prevention. The dose recommended for that is 81 mg a day. The lead investigator in the study, Michelle Holmes, MD, DrPH, is hoping other trials will confirm the findings, which will means aspirin will become a low-cost, effective tool against breast cancer. Who would have ever thought it? By the way, researchers found that women who took non-aspirin, non-steroidal inflammatory drugs (NSAIDs) six or seven days a week, also had a reduced risk of breast cancer death around 48 percent, but women who took NSAIDS less frequently and those who used acetaminophen did not experience such benefit. So, add an aspirin a day to your list.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL